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Abstract 
This examination of prescription drug expenditures and the usage of formularies in 
managing drug utilization is divided into two main sections. First, the prescription drug 
industry is studied for reasons why drug costs are increasing so dramatically in recent 
years. Statistics are given to explain why there should be a concern in our society about 
this trend, and the therapeutic classes are identified to show where the most money is 
being spent. The following possible reasons for increasing drug expenditures are 
discussed: increasing prices, product shift, higher utilization, patents, research costs, 
decreasing out of pocket expenses, our aging society, and direct-to-consumer advertising. 
In the second section of this paper, a definition of what constitutes a formulary and 
the different types of formularies are explained. Incentives used in open formularies such 
as tiered copays are detailed. Ethical concerns about the usage of formularies are 
outlined, and the process of selecting drugs for a formulary is explained. Different 
pricing techniques for cash customers and third-party coverage(usually employer based) 
are demonstrated. The next part of this section addresses concerns about formulary 
usage, and different ways to respond to these concerns. At the end of this section, recent 
developments with Medicaid formularies are discussed. 
In the final section, a summary of major points is given along with personal 
commentary and recommendations for the future. 
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Introduction 
National health-care expenditures increased by 6.9% in 2000, continuing a trend of 
quick-paced growth that occurred throughout the 1990's.[1] Spending on health-care as a 
percentage of our Gross Domestic Product has been steadily increasing, and reached 
13.2% in 2000, totaling $1.3 billion.[1] The Health Care Financing Administration 
predicts by 2010, national health expenditures will total $2.6 trillion and be 15.9% of the 
GDP.[2] Even with the United States economy growing at a very healthy rate in 1999 
and 2000, health-care expenditure increases still outpaced GDP growth.[1] In terms of 
health-care spending per person there has also been dramatic increases. In 1980, the 
national health expenditure per capita was $1,067. In 2000, our country spent $4,681 per 
person on health-care.[2] 
Although spending in all areas of health-care has been steadily increasing, the 
HCFA notes prescription drug spending accounts for a large share of the increases. Since 
1980, overall health-care expenditures have increased by 433%, whereas prescription 
drug expenditures have gained more than double, 874%.[4] In a snapshot of national 
health-care spending in 2000, prescription drug expenditures accounted for 9% of costs, 
compared to 32% for hospital care, 22% for physician and clinical services, 7% for 
nursing, 6% for administration costs, and 24% for other spending.[3]. In 1980, 
prescription drugs accounted for only 4.9% of total spending, and in 1990 the statistic 
was 5.8%.[4] By 2010, it is projected prescription drugs will account for 13.9% of 
health-care costs. [4] As noted above, national health expenditures accelerated by 6.9% in 
2000, but spending on prescription drugs increased by 17.4%.[4] It is unquestionable 
prescription drugs have had and will continue to have a much larger role in our health-
care system. 
2 
Utilization 
The first step in understanding why prescription drug costs are rising is to identify 
how utilization is allocated between various illnesses and diseases. What diseases or 
ailments do Americans need a prescription drug for? The following table with data taken 
from the National Institute for Health Care Management lists the top therapeutic classes 
in terms of sales, the percent of total sales, the best-selling drugs in the category, the 
market share controlled by the top drugs, and % sale increase from 1999 to 2000. The 
information is taken from Table 2 and Table 5 in the NIHCM report. [16],[17] 
Best-Selling Therapeutic Classes 
Therapeutic 1999 % of Total Top Drugs % of % Sales 
Class Sales in Drug Sales Market Increase 
Millions Share for from 1999 
Of Top Drugs to 2000 
Dollars 
Antidepressants $8,630.4 7.9% Prozac 68.2% 20.9% 
Zoloft 7.6% lAP 
Paxil 12.4% VI 
Wellburtin Sr 
Antiulcerants $7,875.5 7.2% Prilosec 88.3% 20% 
Prevacid 7.6% lAP 
Ranitidine 11.5% UI 
Hcl 
Pepcid 
Cholesterol $6,470.2 6.2% Lipitor 89% 27.4% 
Reducers Zocor 5.3% lAP 
Pravachol 21.0% UI 
Lescol 
Broad $7,331.8 5.9% Cipro 41.8% 6.5% 
Antibiotics Zithromax 7.3% lAP 
Z-Pak -.8% VI 
Levaquin 
Biaxin 
Anti arthri ti c $4,444.8 4.7% Celebrex 52.3% 39.3% 
Vioxx 21.3% lAP 
Enbrel 14.3% VI 
Relafen 
*IAP: Increase in Average Price VI: Utilization Increase 
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In addition to the best-selling therapeutic categories, it is also of importance to note, 
which drug classes are growing the most quickly in terms of price. In 2000, antiarthritic 
drugs led the way with an increase of 21.3%. They were followed by narcotic painkillers 
with 21.1 %, antipsychotics at 16.4%, oral diabetes with 15.6%, and dermal acne therapy 
at 14.8%.[17] 
Although the pharmaceutical industry has thousands of products on the market, it 
may come as a surprise that the top 50 selling drugs make up more than 40% of the 
market. [7] From the chart on the following page, the dramatic difference between the 
best selling drugs and the rest of the market in terms of sales, number of prescriptions, 
sales growth, and price can be seen. These differences will be discussed further in the 
next section. 
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The Prescription Drug Market in 2000 
All Drugs 1999 2000 Percent Change 
Total Sales(billions) $111.1 $132.0 18.8% 
Total Scripts(millions) 2,712.4 2915.2 7.5% 
A vg Price Per Script $40.96 $45.27 10.5% 
50 Best Selling 
Drugs(2000 sales) 
Total Sales(billions) $44.9 $58.2 29.7% 
Total Scripts(millions) 730.6 866.6 18.6% 
A vg Price Per Script $61.41 $67.15 9.4% 
Rest of Market(2000 
sales) 
Total Sales(billions) $66.2 $73.8 11.4% 
Total Scripts(millions) 1,981.9 2,048.6 3.4% 
A vg Price Per Script $33.42 $36.01 7.7% 
50 Drugs Contributing 
Most to Sales Growth 
Total Sales(billions) $37.5 $52.6 40.2% 
Total Scripts(millions) 533.5 693.1 29.9% 
A vg Price Per Script $70.32 $75.88 7.9% 
Rest of Market 
Total Sales(billions) $73.6 $79.4 7.9% 
Total Scripts(millions) 2,178.9 2,222.2 2.0% 
A vg Price Per Script $33.77 $35.72 5.8% 
* Script is abbreviation for prescription 
Table taken from Prescription Drug Expenditures in 2000: The Upward Trend Continues.[7] 
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Causes of Expenditure Increases 
There are numerous reasons why prescription drug expenditures are increasing 
rapidly in the United States. In the following section, a brief overview of these causes 
will be given. 
Product Shift, Increasing Prices, & Rise in Utilization 
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In the case of prescription drugs, the use of new products is labeled "product shift." 
Product shift is demonstrated when new brand drugs are used in place of older and less 
expensive drugs. The costs for these newer drugs are justified by increased health 
benefits to the consumer. Many recent drugs have provided therapies where none have 
existed before, greater-cost effectiveness, and have reduced costs of non-pharmaceutical 
expenditures.[5] For example, in many cases drug treatment is available for ailments that 
in the past would require more expensive surgical procedures. If a drug is noted for 
being more beneficial than others, its utilization will naturally increase. [6] 
In a study done by Mullins et aI, an attempt was made to distinguish rise in drug 
expenditures between product shift, price increase, and utilization increase. Basing their 
study on the American Druggist's top 100 drugs in terms of prescription volume from the 
period 1995 to 1998, they ascertain one-third of expenditures increases were due to 
utilization increases in existing drugs, a little more than one-third because of product 
shift, and a less than one-third from price increases on existing drugs.[6] 
The NIHCM conducted a similar study for factors contributing to retail prescription 
drug spending increases in 1999-2000. Of the $20.8 billion increase in spending, 36% 
was attributable to product shift. Price hikes and rises in the number of prescription 
accounted for 22% and 42% of the expenditure increase, respectively.[17] 
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A verage Price of Old Drugs Compared to New Drugs 
a) A verage Price of An Old Drugs (pre 1992 approval, 1998) 
b) A P 0 ~ n b t T F B t S n° D (2000) vera~e flce or a u op our es - e m~ ru~s 
Therapeutic Class Top Average Therapeutic Class Top Average 
Selling New Drug Selling New Drug 
new Price(2000) new Price(200 
drugs(post drugs(post 0) 
-1992 -1992 
approval) approval) 
Antidepressants Broad Antibiotics 
a) $48.82 Celexa $69.05 a) $25.99 Zithromax $41.00 
b) $45.11 Paxil $78.62 b) $24.89 Levaquin $77.77 
Weilbutrin $85.88 
Oral Antidiabetics 
Anti-Ulcer a) $27.27 Glucopha $63.00 
Ige 
a) $86.99 Prevacid $125.98 b) $34.18 Avandia $116.27 
b) $78.52 Actos $137.57 
Cholesterol Reducers Respiratory Steroids 
a) $71.89 Lipitor $82.58 a) $51.48 Flovent $72.28 
b) $52.01 Zocor $112.36 b) $54.37 Flonase $53.88 
Arth ritis/Osteoarth ritis Estrogen Replacement 
a) not available Celebrex $88.93 a) $26.53 Prempro $34.06 
b) $30.42 Vioxx $79.17 b) $36.35 
HIV/AIDS Narcotic Pain Killers 
a) $318.68 Combivir $551.58 a) not available OxyContin $189.01 
b) $327.70 Viracept $590.84 b) $24.77 
From fIgure 7[17] 
Newer drugs, which often are the best sellers, have increased in price and utilization 
must faster than older drugs. According to the NIHCM, in 2000, pharmacists dispensed 
18.6% more prescriptions than in 1999 for the top 50 best selling-drugs. This compares 
to only an increase of 3.4% for all other drugs. [17] In terms of price increases, the top 50 
selling drugs had an average price of $67.15, compared to only $36.01 for the average 
-
price of all other drugs.[17] From the table entitled "Average Price of Old Drugs 
-Compared to New Drugs", the dramatic difference between the newer, top-selling drugs 
and older drugs in terms of prescription price can be seen. 
Aging Population 
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As the baby-boomer generation creeps into old age, the more elderly United States 
population will demand prescription drugs that can treat chronic conditions and aid in the 
prevention of disease.[8] The growth of Americans in the over sixty-five age category 
slowed in the 1990's due to the decrease of the birthrate during the Great Depression, but 
is expected to have its greatest increase between the years 2010 and 2030 as baby-
boomers reach sixty-five.[9] In 2000, people over age 65 accounted for 13% of the 
population. This will increase to around 20% by 2030.[23] 
The pharmaceutical industry has already geared their research towards medical 
advances that will correspond with the aging of our population. [20] The elderly 
population will have to deal with chronic and disabling diseases that will require new 
drugs.[20] Insurance companies covering older populations have already noted steadily 
increasing drug costs, and believe costs will continue to escalate.[20] The average 
patient over age 65 fills twenty prescriptions per year, compared to only three 
prescriptions for patients in their twenties.[23],[31] The average cost for a person age 65 
to 70 is $700, nine times higher than a person in their twenties.[23],[31] 
Research & Development Costs 
Another factor causing prescription drug costs to rise is the enormous cost of 
developing and researching new drugs. The Tufts Center for the Study of Drug 
Development found a pharmaceutical company typically spends about $800 million over 
a period of ten to fifteen years to develop a new drug.[10] This cost is up from a similar 
study done by Tufts in 1987 which put the price at $231 million.[II] If adjusted for 
-inflation, the 1987 cost would be only $318 million.[ll] In terms of overall revenue, in 
2000, research and development spending was around 15% to 18% of drug 
manufacturers' total revenue.[37] What makes drug development cost so much? 
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Prescription drug research and approval is a long a tedious process. The process 
begins by a new drug being developed by a sponsor, which could be an individual, 
partnership, corporation, government agency, or scientific institution.[lO] The sponsor 
then must file an initial new drug application with the Food & Drug Administration if it 
intends to conduct clinical studies.[lO] The chances of a new substance even reaching 
this step are extremely slim. The Pharmaceutical Manufacturers of America claim that of 
every 1,000 medicines tested, only one is tested in clinical trials. [10] 
Once a prescription drug reaches the clinical trials stage, its approval for 
marketplace use is by no means assured. The clinical phases are the longest and most 
expensive part of drug development, and represent a significant investment on the part of 
the pharmaceutical manufacturer.[12] Clinical development usually has three phases of 
study.[lO] Phase I involves studying volunteers to see how the drug affects the general 
processes of the body and what side effects may occur. [10] After the first phase, the 
company decides if the results favor starting Phase II. Phase II determines if the drug is 
effective in treating the disease or ailment it is intended for. [10] Phase III studies 
generally have hundreds to even thousands of patients in controlled and uncontrolled 
trials. The purpose of Phase III is to find data that will be eventually be put on physician 
labeling. [10] 
From a drug's synthesis, until it reaches the marketplace, the average time is around 
twelve years.[12] After making such a significant investment in research and time, the 
pharmaceutical company hopes to recoup its expenditures by having tremendous sales of 
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the product. Naturally, these companies do not want other companies benefiting from 
their difficult work, therefore, patents are used as a reward to compensate pharmaceutical 
companies for their costs in bringing a drug to the marketplace.[13] 
Patents 
Patents grant temporary legal monopoly power to the maker of a specific drug.[14] 
Currently in the United States, patents have a period of either twenty years from the date 
of filing or seventeen years from the date of grant, whichever is longer.[15] Without 
patents, drug manufacturers would not have the financial incentive to devote millions of 
dollars of research and development to the production of a new drug.[14]. At the same 
time, the use of patents is obviously going to limit competition which in tum will cause 
higher prescription drug prices.[14] 
Pharmaceutical manufacturers have been increasing their research and development 
budgets with the expectation of patent protection for their new drugs.[14] Over the past 
decade private funding of biomedical research and development has surpassed 
government spending in the area despite the budget for the National Institute of Health 
being doubled at the same time.[13] Pharmaceutical manufacturers continually say they 
cannot cover their research investments without patent protection. [13] 
Direct-to-consumer Advertising 
In the last few years, most Americans have surely noticed an increase in 
prescription drug advertising, and data supports these findings. According to the 
National Institute of Health Care Management, after the FDA changed the rules on 
prescription drug advertising in 1997, spending on direct-to-consumer advertising has 
gone from $1.1 billion in 1997 to $2.5 billion in 2000.[18] Of the $2.5 billion of direct-
to-consumer advertising in 2000, 57.2% was composed of television ads, 11 % on the 
10 
radio and billboards, and 31.8% in magazines and newspapers. [18] For example, the 
antiarthritic drug Vioxx had $160 million in direct-to-consumer advertising(DTC), 
beating Pepsi, Budweiser, Nike shoes, and equaling Dell's expenditure on its best-selling 
computer line.[18] 
Obviously, the drug companies must be having some success with their DTC, or it 
would not be worth the tremendous amount of money they have spent. In a study done 
by Scott-Levin, doctors noted an 11 % increase in office visits by patients visiting for 
greatly advertised conditions from January to September 1998. During the same period, 
there was only a 2% increase in total office visits. [20] Also, in a recent study done by 
IMS Health, it was reported 42% of physicians reported an increase in requests for a 
specific brand name drug by patients. [43] Additionally, physicians found 86% of their 
patients first learned about a brand name drug through a manufacturer's ad.[43] 
The focus of DTC advertising has been on conditions that are chronic, non-life 
threatening, widespread amongst the public, and the people affected often go 
untreated.[5] The statistics support this claim very well. Vioxx, the anti-arthritic 
medicine, ranked number one in DTC advertising with $160.8 million. It was followed, 
in order, by Prilosec(antiulcerant), Claritin(oral antihistamine), Paxil(antidepressant), 
Zocor(cholesterol reducer), Viagra(sex function disorder), Celebrex(antiarthritic), 
Flonase(respiratory steroids), Allegra(oral antihistamine), and rounding out the top ten 
was Meridia(anti-obesity).[18] 
A study done on ten popular magazines with a diverse reading population gives 
more information about what drugs are advertised most heavily. It was found that 
advertisements for drugs providing symptom relief accounted for 63% of all 
advertisement.[18] In this category, the most prominent advertisements were related to 
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allergies and menopause-related symptoms.[18] Medications designed for specific 
diseases were second with an advertising share of 26%.[18] The main diseases targeted 
were Alzheimer's, diabetes, mv, depression, fungal infections, arthritis, and 
hypertension[18]. Only 11 % of drug advertisements were for preventive medicines 
targeting smoking, osteoporosis, breast cancer, and cholestrol.[18] 
Below Chart taken from Prescription Drugs and Mass Media Advertising, 2000. Figure 1[42] 
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What rules does the FDA have for prescription drug advertising? The drug 
advertisement may not claim it is superior to another drug without scientific data. Also, 
the advertisement should show a fair balance between the benefits and risk. If the 
-advertisement is in a print media, it must have a summary of the effectiveness, adverse 
effects, and warnings about its use. 
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Why are some experts concerned about drug advertising? The main argument is 
that DTC increases patients' demand for more specific and expensive drugs, which has a 
negative effect on their relationship with their physicians and medical practice in 
general.[19] If patients are making self-diagnosis, the physician may have to explain 
why the medication advertised is not appropriate. [53] A 1998 survey done by IMS health 
reported 53% of physicians reported an increase in brand name requests, a 30% increase 
from mid 1997(before the advertisement regulations were relaxed). [20] Doctors are also 
likely to give the patient the drug they ask for. In a study done by Prevention and the 
American Pharmaceutical Association, 73% of consumers claimed their doctors fulfilled 
a specific drug request. [20] 
One specific example of consumers being led by DTC advertising occurred in New 
York. A health plan introduced a higher $50.00 prescription copayment on a non-
preferred, non sedating antihistamine. Despite the higher payment the consumer had to 
make, and the fact another drug on the market was more effective, the health plan saw no 
decrease in patient use. The health plan presumed this was the effect of DTC 
advertising. [23] 
An argument could be made that heavily advertised drugs are utilized more because 
they are newer and more effective. However, a study done by the National Center for 
Health Statistics and Centers for Disease Control and Prevention from 1997 to 1999 
found this theory to be somewhat flawed. The analysis found the drugs most often 
prescribed were also the drugs with the most advertising spending.[18] 80% of drugs 
reaching the market place in the last several years that had considerable consumer 
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advertising were in the top 20% in terms of utilization. [18] A striking difference is that 
only 10% of recently developed drugs not heavily advertised are in the top 20%.[18] 
There are also people who argue that drug advertising educates consumers about 
conditions and treatment options. [20] If a person hears about a new drug or medical 
practice through an advertisement, this could stimulate dialogue with their doctors, and 
help improve their overall health.[20] 
Increased Third-Party Coverage 
With the rapidly increasing prescription drug costs in this country, how much of it 
are consumers spending out of their pocketbooks? In the beginning of this paper, it was 
noted prescription drug costs have increased 874% since 1980, but how much of the 
increase is covered by third-parties(employer based health plans) rather than by 
consumers themselves? 
Out of Pocket Prescription(OoP) Drug Expenditures as a % of Total Health and 
Prescription Drug Spending($ BiIlions)[21] 
Year Rx % of Health OoPRx %ofRx Health OoPRx as 
Expenditures Expenditures Expenditures Spending Expenditures % of Health 
Expenditures 
1980 $12 4.9% $8.4 70.0% $245.8 3.42% 
1990 $40.3 5.8% $23.8 59.1% $695.6 3.42% 
2000 $116.9 8.9% $40.2 34.4% $1311.1 3.07% 
From the above table, it is obvious consumers are paying a smaller portion of 
prescription drug spending. Although this data is not in the table, out-of-pocket spending 
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for all health care expenditures has gone from 23.7% in 1980, to 19.8% in 1990, and had 
decreased even farther to 15.4% by 2000.[22] What entities are picking up for the drop 
in consumers' share of prescription drug expenditures? 
Division of Prescription Drug Expenditures($ Billions)[21] 
Rx OoP Rx Private Health Federal State and 
Expenditures Insurance Local 
1980 12 8.4 2.0 0.9 0.8 
1990 40.3 23.8 9.9 3.2 3.4 
2000 116.9 40.2 51.3 5.1 4.4 
Division of Prescription Drug Expenditures(% )[21] 
Rx OoP Rx Private Health Federal State and 
Expenditures Insurance Local 
1980 100.0% 70.0% 16.7% 7.5% 6.7% 
1990 100.0% 59.1% 24.6% 7.9% 8.4% 
2000 100.0% 34.4% 43.9% 4.4% 3.8% 
From the above tables, you can see private health insurers are the main source of 
funding for prescription drugs. With the United States labor market being very tight 
throughout most of the 1990's, employers used more extensive prescription drug 
coverage to increase retention and productivity.[31] Typically, an insured will pay a 
copayment or coinsurance to the pharmacist upon receiving their prescription. [5] Even 
though private health insurers prescription drug expenditures increased annually over 
15% in 1996, 1997, and 1998, recipients of the drugs had out-of-pocket payments 
increase by only about 5% each year.[5] Ernst Bendt notes in an insurance-protected 
environment, it is expected that employees' prescription drug use will increase.[5] 
Because of the drop in out-of-pocket prescription drug expenses, some experts feel 
consumers are not concerned about price at time of purchase.[17] Without being 
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concerned about prices, many consumers want to buy the latest and most expensive 
drugs. [17] 
16 
Drug Formularies 
Introduction 
With any resource that is limited, it is necessary to manage and use the resource 
effectively in order for it not to be exhausted. For example, when a part of the United 
States experiences a prolonged drought, water usage does not continue on a normal basis, 
but must be reserved or contained for the most beneficial uses. If this did not occur, the 
water supply might be exhausted and the area could suffer severe consequences. In the 
same way, prescription drug usage must be managed and used effectively. Health plans 
and employers could not afford to provide a prescription drug benefit if the demand for 
drugs was left unconstrained. In a typical drug benefit plan, there are usually several 
methods of managing utilization. One such tool that is widely used is drug formularies. 
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Definition 
What exactly is a drug formulary? The Managed Care Handbook defines a drug 
formulary by the following: a preferred list of medications developed by the health plan 
or pharmacy benefit manager to guide physician prescribing and pharmacy dispensing. 
The purpose of a drug formulary is to control inventory and encourage the use of the 
most cost-effective products.[24] A formulary will generally contain information about 
drugs eligible for coverage in each therapeutic class, whether a brand-name or generic is 
covered, coverage restrictions, cost index, and a copayment classification. [24] Further 
explanation of these characteristics will be done in the following sections of this paper. 
Formularies are popular with managed care organizations(MCQ's) because they 
control both the supply and demand for prescription drug products by sharing the 
financial risk with employees, medical networks, and even physicians.[24] In the 
following section, it will be shown how formularies allow the financial risk of a drug plan 
to be shared with all three entities. 
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Types and Structures of Formularies: 
There are two main types of prescription drug formularies: closed and open. With a 
closed drug formulary plan, a consumer will not be covered if a drug is not listed in the 
formulary unless special approval is granted by their health plan. [27] Normally, only a 
benefit is included for generic and preferred brand-name drugs.[31] About 10% of all 
health plans operate with closed formularies, but are found in 27% of all HMO's. [27] 
An open drug formulary is much more prevalent than the closed version because 
consumers are not very enthusiastic about having their drug choices limited, and do not 
like the hassle of getting special approval for a particular drug. [27] Instead of forcing 
people to select certain drugs like a closed formulary, an open formulary instead gives the 
buyer and others incentives to select specific drugs in each class.[27] 
One such incentive are copayment tiers. Approximately 80% of managed care 
plans are now offering a tiered prescription program with their drug benefit plan.[31] 
When a consumer purchases a drug, he or she will pay a fee at the time of purchase 
referred to as a "copay." Copayments are used to make consumers share in the financial 
risk of drug costs.[24] A person is likely to think twice about paying for a particular drug 
if they have to pay for a share of the cost. Copays help eliminate frivolous prescription 
drug use.[24] 
With tiered copayments, there are generally three different classes differing by 
amount and type of drugs, and occasionally a fourth tier for "lifestyle drugs". [28] The 
table on the next page describes the characteristics of the various tiers, with the 3rd row 
describing a common copay for each tier. 
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Tier I Tier II Tier III Tier IV 
Generic Copayment Preferred Brand Non-Preferred Brand Nonformulary products 
<$10 $10 to $25 $15 to $40 50% of cost up to a max 
[28] 
From the table above, Tier I has the lowest copayments because generic drugs are 
much cheaper than brand-name drugs, and the lower copayment is an incentive for the 
consumer to select a generic drug if possible. [24] Tier II drugs are generally shown to be 
more effective or less expensive than drugs from the same therapeutic class. The 
copayment is less for Tier II than Tier III to encourage Tier II selection. Tier IV is 
reserved for drugs referred to as "lifestyle drugs"(Viagra is one example).[24] The goal 
of tier usage is to provide the consumer with more selection, but to require the patient to 
accept the yd or 4th tier copayment if a more costly or unnecessary drug is selected.[24] 
Another incentive used by open formularies that is very effective at cost-
containment is a mandatory generic substitution program. [28] The health or drug plan 
agrees to pay the pharmacist only the Maximum Allowable Cost(based on the lowest 
estimated acquisition cost for any of the generic equivalents of a given drug), whether the 
drug is generic or brand-name. The patient will end up paying the difference between the 
brand-name cost and the MAC.[24] 
Physicians and pharmacists can also be influenced to prescribe and dispense drugs 
on a formulary. Many drug plans have linked compensation for plan-affiliated physicians 
and pharmacists to their following of formulary guidelines.[33] For example, if a 
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physician's prescribing practices were lower then the average physician linked to the 
health plan or if they switched patients from expensive brand-name drugs to generics, the 
physician could receive a bonus for his cost-saving efforts. 
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Ethical Concerns 
Is it ethical to limit drug choices or to make consumers pay more for certain drugs? 
According to Burton et aI, limits on coverage and use of drugs are an ethical requirement 
and economic necessity. [30] However, when constraints are in place, they must serve 
their intended purposes or become nothing more than a burden. If a drug formulary is not 
saving consumers or the health plan any money, there is no point for it to be in place.[30] 
The main and primary goal of any medical practice is to help the sick. A health 
plan should therefore make sure all members have access to drugs that are necessary for 
surviva1.[30] A well designed formulary should help payers save money on life 
enhancing and life lengthening drugs, which also happen to be areas of greatest spending 
increases.[31] It is also important that low-income consumers have affordable access to 
the drugs they need. [30] For example, a drug that is used only to enhance one's 
lifestyle(such as Viagra), should be more expensive to consumers than a drug that could 
be the difference between life and death. 
Another important ethical requirement between health plans and consumers is 
trust.[30] If a person thinks their formulary plan is created to put them at a disadvantage 
or cheat them out of certain drugs, he or she will likely be dissatisfied with the health 
plan. [30] 
A drug formulary must also be trusted by physicians. [30] A physician has a 
medical responsibility and goal of giving patients the best treatment possible. If the 
physician feels the drug formulary inhibits how he or she practices medicine, there could 
be a conflict of interest between the health plan and physician.[30] 
There is also an ethical concern about giving physicians financial incentive, as 
mentioned before, to select drugs on a formulary. The American Medical Association 
22 
believes such practices should be permissible only if they promote cost effectiveness, and 
not when patient welfare is compromised. The AMA recommends that financial rewards 
should be done on a group basis, and should not be done on a physician by physician 
basis.[33] 
When a drug formulary is designed, the considerations of not just a few individuals, 
but all members must be incorporated. Burton et al believe foregoing formulary 
restrictions for one individual's needs can make all restrictions objectionable. [30] If very 
expensive medications are provided to certain patients, then this could drive up costs for 
all members, and leave very poor and sick patients with a lack of coverage. [30] 
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Formulary selection: 
Phannacy & Therapeutics Committee 
How do certain drugs make a formulary, and what are the main factors influencing 
selection? The body that makes such decisions is called a "Pharmacy and Therapeutics" 
committee, and is composed of a committee of experts consisting mostly of physicians 
and pharmacists. [24] The P&T committee must determine a drug coverage policy and 
how it will be implemented, along with how to educate various people in the utilization 
process(manufacturers, physicians, pharmacists, consumers).[24] The committee will 
meet frequently to update their drug formulary selections. 
There are several factors a drug must satisfy in order to be placed on a formulary. 
According to the Managed Care Handbook, the P&T committee considers the following 
criteria: source of supply, reliability of manufacturer and distributor, drug class, similarity 
to existing drugs, clinical advantages, dosage ranges, and cost comparisons.[24] The 
committee will consider peer reviewed material when making drug selections, along with 
information from manufacturers, albeit a degree of bias is always looked for when 
reading data directly from manufacturers. [24] The committee will also consider research 
done on a managed care organization with a similar member demographics. [24] 
Phannacoeconomics 
One tool that is being used more frequently in formulary development is 
pharmacoeconomics. Pharmacoeconomics is defined as identifying, measuring, and 
comparing the costs and conquests of pharmaceutical products and services.[55] The 
goal of pharmacoeconomic studies is to enable health care experts make better decisions 
that will benefit the overall health of the public, and will allow us to measure value 
between differing treatment options.[55] 
-24 
For formulary development, it is suggested that an effective pharmacoeconomic 
approach should emphasize pharmaceuticals that are expensive, have high utilization 
rates, and make a large impact on public health.[55] Expensive drugs should be targeted 
for study because their higher costs should be justified by added health benefits. J.D. 
Kleinke refers to such drugs as "fast pays."[50] Fast pays are characterized by lower-
short term medical costs for patients compared to alternative therapies, such as 
surgery. [50] 
Pharmacoeconomics attempts to determine the cost per outcome of different 
treatment options. [55] The measures of costs can be by a clinical, economic, or 
humanistic means.[55] If a drug is found to lower blood pressure, prevent strokes, or 
reduce heart attacks, this would be a good measure of clinical outcome.[55] The 
economic measure of a therapy would be completed by examining costs undertaken and 
costs avoided by a decision. [55] Humanistic measures would include quality of life, 
increased life expectancy, and patient satisfaction. [55] By using these three different 
measures, one could determine the cost per treated patient, clinical outcome achieved, life 
years gained, or event avoided.[55] 
To find the data necessary for such studies, it is suggested a formulary development 
committee looks at a number of data sources. First, the committee could look at data on 
the characteristics of its enrollee population.[55] Is the population relatively old or 
young? Are there the same numbers of males as females? What health services are the 
enrollees more likely to utilize? Next, the committee might examine claims to determine 
which diseases are more prevalent, and how many of the enrollees are affected. The 
committee could determine what areas of health the formulary should be most concerned 
with.[55] 
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Once the formulary is developed through a pharmacoeconomic approach, the 
rationale for the decisions should be explained to both patients and physicians.[55] 
Because the formulary was researched and developed carefully, plans using 
pharmacoeconomic approaches generally deal with less non-formulary requests. [55] In 
the near future, more health plans will likely using this very valuable technique when 
selecting drugs for their formularies. 
-Drug Manufacturers and Formularies 
Example 
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What incentive does a drug manufacturer have to get their drug on a formulary, and 
how does this affect prescription drug pricing for people under different forms of 
coverage? Imagine you are trying to sell a product you have just invented. One person 
talks to you and says he would like to purchase your product for his own use. Another 
person then contacts you, and says he and 30,000 of his friends would like to buy your 
product, but only if they are given a discount from what the first person paid. Naturally, 
you agree to such a deal because with the amount of volume you will sell, a nice profit 
will be made. This is similar to how drug pricing works. When a managed care plan 
approaches a drug manufacturer, they have much more clout than a single person. In 
economic terms, this is referred to as price discrimination.[27] 
Theory of Price Discrimination 
Before the process of drug pricing is explained, the theory behind the process will 
be shown. For price discrimination to exist in a market, three criteria must be met. First, 
the product seller must have some form of monopoly power. If this were not the case, the 
seller would be unable to set different prices for various groups or individuals. [28] For 
drug manufacturers, patents give them temporary monopoly power over their 
products. [27] 
Second, the seller must be able to judge approximately how much various buyers 
are willing to pay for their product. The seller has to be able to divide its buyers into 
various groups or segments and determine the elasticity of demand between different 
groups.[28] When drug classes have multiple products to choose from, large health plans 
become very responsive to price and have the ability to redirect the market share of the 
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drug class by changing what drug is on their formulary. Manufacturers, naturally not 
wanting to lose market share, will be very careful about not charging the health plan too 
much for their products. [27] 
The third and final criteria for price discrimination is the ability to prevent resale or 
arbitrage of the product.[27] For example, if a large enough discount was given to a 
group of people to purchase OM cars, they might buy the cars, and then try to sell them to 
the general public for a profit. This generally does not happen with prescription drugs 
because of laws and regulations. [27] The Prescription Drug Marketing Act of 1987 sets 
rules for how and who can resell drugs. The PDMA forbids groups such as hospitals, 
nursing homes, and HMO's from engaging in arbitrage.[28] 
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Process of Determining Prices 
How does price discrimination influence how much you pay for a drug at your local 
pharmacy? The price you pay will be more if you are uninsured or have indemnity 
coverage, than if you were part of a managed care plan. According to the Department of 
Health & Human Services, a cash customer will generally pay 15% more than a customer 
in a third-party drug plan, and the gap in price differences has been increasing in recent 
years. [25] To understand how this price difference is gained by third party 
administrators, an examination of drug pricing outside of a managed care plan will be 
first explained, and then the managed care pricing process will be shown. 
Pricing for a Cash Customer: 
The process of setting a price for your prescription begins naturally with the 
manufacturer.[25] The manufacturer will set a price for their product depending on a 
number of market inputs. First, the form and strength of the product is analyzed.[25] If a 
pill is only needed to be taken once a day, it will be more expensive compared to another 
pill serving the same purpose that must be taken ten times a day. The manufacturer also 
looks at how much competition their drug if facing. [25] For example, if only one drug 
existed for a certain disease, the manufacturer would be able to command a high price 
without worrying about a drop in market share. Generic drugs are much cheaper than 
brand-name drugs because the market is flooded with manufacturers.[25] 
A manufacturer will often distribute their drugs to what is known as a "wholesaler." 
Wholesalers will buy large volumes of a drug and then distribute them to pharmacies. [25] 
The manufacturer's price of a drug does not necessarily reflect development costs. A 
manufacturer who is trying to get their specific drug to gain market share will often offer 
--
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the drug at a discount to a wholesaler, hoping the wholesaler will be able to distribute the 
drug to pharmacies and increase demand for their product.[25] 
"Average wholesale price" is the term for what pharmacies pay to wholesalers to 
acquire drugs they will distribute to consumers. A WP is not the average cost incurred by 
pharmacies, but is a price recommended by the manufacturer of the drug. [25] The 
pharmacy will pay the acquisition cost of the wholesaler, plus an additional fee added by 
the wholesaler. The wholesaler generally is able to purchase drugs twenty percent below 
the AWP, and then sells them to pharmacies at a two to four percent markup.[25] 
The final cost paid by the consumer includes the transaction cost the pharmacy 
incurred for acquiring the drug from the wholesaler, plus a charge for the cost of filling 
the prescription. [25] A customer with indemnity coverage may pay the full price, and 
then be compensated by his or her insurer. Because of economies of scale, a large 
pharmacy chain will usually be able to fill prescriptions at a cheaper rate than a small-
independent pharmacy.[25] Pharmacies generally charge the consumer a price twenty-
five percent above their acquisition cost to pay for expenses, taxes, and of course 
profits. [25] 
Pricing for Third Party Coverage 
For third party coverage, a new entity comes into play for prescription drug pricing. 
Since appropriately used pharmaceuticals are one of the most cost efficient forms of 
therapy, it is only natural for a managed care organization devoted solely to 
pharmaceuticals to exist. [24] Pharmacy benefit managers(PBM's) are able to manage a 
drug benefit for a large group of people, and therefore have the leverage to negotiate with 
retail pharmacies and manufacturers for discounts. [25] 
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According to the Managed Care Handbook, a PBM will own or contract with 
community pharmacy providers to control both the drug ingredient cost and 
administrative costs. [24] The PBM has three different types of pharmacies at its disposal 
to distribute drugs to members: owned, in-house pharmacies within health plan medical 
centers, independent and chain community retail pharmacies, and mail service or Internet 
pharmacies.[24] PBM's have several different stipulations for members and pharmacists 
in order to keep their costs down.[24] 
For the PBM and the pharmacy network to enter into a contract, it must be mutually 
advantageous for both of the entities. By entering into a contract with a PBM, the 
pharmacy must follow a number of rules. First, the pharmacy agrees to accept a defined 
reimbursement for each prescription filled for a member of the drug plan. This 
reimbursement is usually a 15% discount of the A WP for brand-name drugs and 50% off 
the AWP for generic drugs.[24] Second, the pharmacy must agree to a set dispensing fee, 
on average about $2.50.[24] When determining discounts, a PBM will generally take 
into account the pharmacy's cost for acquiring the drugs from a wholesaler. [25] Also, 
the PBM might offer a higher price to large retail pharmacies rather than small 
independent ones.[25] For a small pharmacy network, members might complain if they 
have to travel long distances to fill their prescriptions.[31] Third, the patient cannot pay 
more than their copayment(what the patient pays at the time of purchase), and the 
pharmacy must agree to accept the PBM reimbursement as the full payment.[24] Finally, 
the pharmacy must agree to dispense drugs according to the drug formulary.[24] 
For a pharmacy network to enter into such an agreement, the benefits must be 
considerable. The PBM must agree to have all their members obtain prescriptions from 
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the contracted pharmacy only. [24] When a pharmacy is contracting with the PBM, they 
are basically buying customers. 
A PBM can also obtain discounts directly from a manufacturer. The PBM can get a 
negotiated rebate with a manufacturer if the PBM agrees to put the manufacturer's drug 
on their formulary. [25] These rebates average 10% to 12% of the original cost, and can 
rise as high as 15% to 17% if the drug shows rising market share.[37] 
Manufacturers of brand-name drugs for therapeutic classes where several 
alternative therapies are available have a strong incentive to offer the PBM discounts in 
order to be on a formulary, or else risk losing market share.[25] Mary Kuhn, Vice 
President of North American Operation for Bayer's pharmaceutical division, adds that 
drug manufactures will sometimes "bundle" fast-selling products and those that are 
having more trouble gaining market share.[31] Another technique drug manufacturer's 
use is offering deep discounts on a product when it first is introduced to the market.[31] 
There are three main tools the PBM has at its disposal to obtain price savings from 
the drug manufacturers: chargebacks, rebates, and discounts.[27] A wholesaler usually 
buys a large volume of drugs at the wholesale acquisition cost(W AC), and then 
distributes them to various pharmacies at the WAC, plus the distribution fee. The PBM 
will negotiate for manufacturers discounts with certain pharmacy networks, so some 
drugs can be obtained for even less than the WAC. The wholesaler will then 
"chargeback" the manufacturer for any difference between what the pharmacy paid and 
what it paid originally. If chargebacks did not exist, wholesalers would be distributing 
drugs for less than their acquisition cost, which would be a very bad business 
practice. [27] 
32 
For an example of a chargeback, the manufacturer and PBM agree on a price of $25 
for each prescription of a certain drug. However, the wholesaler must pay the 
manufacturer $30 to buy the drug. The wholesaler would then get a charge back of $5, 
the difference between what the wholesaler and PBM pay, from the manufacturer for 
each prescription. 
Rebates are used as an incentive for PBM' s to increase the market share of a 
manufacturer's drug. [27] Rebates only involve the manufacturer and the PBM, and the 
savings to the PBM are retrospective. [27] Suppose a drug manufacturer approaches a 
PBM, and agrees to give a 10% discount if the PBM successfully introduces its drug to 
its enrollees. If the PBM is successful, the PBM will get a discount. If the PBM failed, 
no discount would be given. 
Only HMO's and hospitals that have in-house pharmacies and the ability to buy 
drugs directly from the manufacturers use direct discounts. The manufacturer simply 
reduces the price for drugs the groups buy.[27] A wholesaler is not involved in this 
process. 
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The following table illustrates how the price differences between cash and third-
party customers are obtained. Table taken from April 2000, "Report to the President 
Prescription Drug Report", done by the Department of Health and Human Services.[44] 
Illustrative Example of Pricing for Brand Name Prescription Drugs 
Cash Customers Insurers and PBMs 
List Price(A WP) $50 
Manufacturer's $40 $40 (excludes any rebates) 
Price(manufacturer to 20% off AWP 20% off AWP 
wholesaler or other entity) 
Acquisition Price $41 $41 
(wholesaler to pharmacy) 
Retail Price at Pharmacy $52 $46(excluding rebates) 
(total of amounts paid by 
customer and reimbursed by 
3rd party payer) 
Retail Price, less typical N/A $30 to $44 
manufacturer rebate 5% to 10% rebate 
Ultimate(net) amount paid $52 $30 to $44 
by final purchaser and/or 
customer 
-Addressing Concerns with Formularies 
Agency Relationships 
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In the United States' phannaceutical utilization system, the entities that carry out its 
various functions have very dependent relationships. For example when you go to a 
doctor, you depend on him or her to select the right drug for you.[26] You also are 
hoping your insurance plan will be helping offset the cost of the drug, and drug 
manufacturers will be producing the drug you need. [26] If any of these three groups did 
not perfonn the job you expected, trouble would likely be ahead. 
Why do such dependent relationships exist? According to Mott et aI, parties are 
interdependent because they either do not have the specialized knowledge and skills to 
perfonn an action or the acquisition of the knowledge and skills is too costIy.[26] Who 
would want to go to medical school just so they could select their own prescription 
drugs? Such relationships where one party(principal) depends on another party(agent) to 
perfonn an action for the principal's benefit, an agency relationship develops.[26] 
Agency relationships work fine, unless the agent begins acting not in the best 
interest of the principal. Mott et al describes the agents perfonnance as an outcome that 
varies between perfect and imperfect. [26] There are several examples of agency 
problems involving prescription drugs 
Conflict of Interest for Physicians 
In the case of fonnularies, there has been questioning about whether the relationship 
between physicians and drug manufacturers influences fonnulary selection and drug 
prescribing.[32] Recalling many physicians serve on P&T committees to select 
fonnulary drugs, this is a grave concern. In a 1994 study done by Chren and Landefield, 
it was found physicians who received monetary support from drug companies for travel, 
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lodging, speaking, engagements, or research expenses, were more likely to request drugs 
to a formulary produced by the supporting manufacturers, even if little or no advantage 
existed over similar drugs already on the formulary.[32] The study concludes there may 
be a need for stricter guidelines to minimize physician relationships with drug 
manufacturers. [32] If physicians on P&T committees are not selecting the most cost-
effecti ve or best-value drugs, the goal of the formulary is being undermined. [31] An 
agency problem will develop if physicians are not carrying out the intentions of the PBM 
by selecting improper drugs for the formulary. 
To combat agency problems arising from a physician on a P&T committee who has 
a relationship with drug manufacturers, the Academy of Managed Care Pharmacy makes 
a few suggestions. First, require P&T committee members to reveal any economic and 
other relationships with pharmaceutical entities that could influence formulary decisions 
by signing a conflict of interest statement. [36] Second, product sponsor representatives 
should not be allowed membership on a P&T committee nor admittance to any 
meeting.[36] Finally, committee members must follow policy concerning disclosure of 
any conflict of interest during discussion of formulary policy. [36] By following these 
three guidelines, the formulary should be able to be properly created and administered 
without any improper influence by pharmaceutical manufacturers. 
When physicians are prescribing a drug, they are often unaware of the price, 
effectiveness, and risk of substitute products. [32] The physicians lack of knowledge 
about these attributes is caused by their lack of financial responsibility for drug 
selection.[32] It is typical for physicians to select a costly brand-name drug in place of a 
generic for two reasons: less liability in a malpractice suit and usually a brand-name drug 
has a simpler name than the chemical version of the generic drug.[32] 
-Web-based Prescribing Tools 
A recent technological innovation has allowed physicians to prescribe drugs more 
efficiently, safely, and effectively. Physicians are using web-based tools that will help 
them select the right drug for a patient, look at any side-effects of the drug, check for 
formulary compliance, and electronically send the prescription to the pharmacy of the 
patient's choice. [37] 
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How effective are these new tools with helping physicians comply with formularies 
and whom do they help? In a study done by Cap Gemni Ernst & Young, physicians 
using a personal digital assistant(PDA) prescribed drugs on a formulary 96% of the 
time.[39] Physicians normally succeed in prescribing a formulary drug 85% to 89% of 
the time. [39] By adhering to the formulary more often, physicians will not only save 
themselves trouble, but also pharmacists and the PBM. If the drug is already on the 
formulary, the pharmacist does not have to spend time calling the physician to make a 
switch to a formulary drug.[39] The study also found the devices generated a higher 
generic substitution rate.[39] This is good news for pharmacies because they generally 
make more money off generics than brand-name drugs. [39] The PDA's also cut out 
illegible prescriptions that cause pharmacists further headaches. [37] The PBM will 
benefit from PDA's because of better formulary compliance and increased use of 
generics. The study also importantly noted physicians using the PDA's did not increase 
drug utilization.[39] 
In addition to helping with formulary compliance, the web-based devices should 
also reduce prescription errors. The Institute for Safe Medication Practices estimates that 
approximately 7,000 people are killed annually due to medication errors, and prescribing 
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errors cost around $77 billion each year.[38] In a study done by Brigham and Women's 
Hospital in Boston, by using computerized prescribing devices, serious medication errors 
decreased by 55%.[38] 
Pharmacists' Role with Formularies 
A pharmacist is usually in the position to determine whether or not generic 
substitution can be carried out, and therefore playa key role in formulary 
compliance.[32] Pharmacists do have a financial incentive to dispense generic drugs 
because the profit margins are often higher on generics than on brand-name drugs.[32] 
Customers will also show greater loyalty to a pharmacist if it is shown to them that 
generics consistently save them money. [32] Possible reasons pharmacists might not 
dispense generics are concern about quality and added time spent communicating with 
the consumer about why the switch from brand-name drug to generic was made.[32] 
From the previous discussion, it is evident that PBM's are very dependent on 
physicians and pharmacists to make decisions consistent with the goals of a formulary. It 
appears that pharmacists have a more vested interest in complying with formularies, and 
the concern over agency problems mostly centers on physicians. In order for a formulary 
to be as effective as possible and not an administrative burden, all parties involved must 
be first concerned with patients receiving high-quality care. 
Quality of Care & Formularies 
One complaint often heard about formularies is that all patients do not respond the 
same to a certain drug, and often only one drug is the most effective in a therapeutic 
c1ass.[33] Studies backup up this concern and show only 50% to 60% of all 
pharmaceuticals are easily interchanged with other drugs in the same therapeutic 
c1ass.[37] It is argued if one patient suffers because of not receiving the best drug for him 
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or herself, then the increased number of office visits and hospitalizations will outweigh 
the savings from other patients.[33] Often a drug is selected to a formulary on the basis 
of average patient-outcome, and individual effectiveness is ignored.[33] 
The more open a formulary, the more responsibility physicians are given to choose 
the best drug. [34] Additionally, the American Medical Association believes a physician 
is ethically required to ask for a formulary addition for an individual patient if the patient 
will respond better to treatment from a particular drug.[33] 
In a recent study done by Schweitzer, a correlation between formulary generosity 
and health plan member satisfaction was analyzed. Two therapeutic classes, calcium 
channel blockers and antidepressants, and 19 different health plans were studied on how 
satisfied enrollees were with their drug coverage and overall treatment.[34] The health 
plans' drug coverage variation was divided into 5 categories: most generous, generous, 
medium, frugal, and most frugal.[34] Of the 19 plans, 4 were defined as being generous, 
2 as most frugal, 2 frugal, and the other 11 plans were medium. [34] The study concluded 
the correlation between formulary generosity and health plan satisfaction was not 
statistically significant.[34] Schweitzer believes one possible reason for this result is the 
lack of enrollee education about the differing amount of drug coverage amongst various 
plans. [34] 
Research has also shown managed care organizations will make sure consumers 
have access to expensive drugs if there is no substitute available in the therapeutic 
class.[40] If a brand-name drug has no generic substitute, the drug wiIl usually not be 
placed on the highest tiered copay.[40] Mea's are well aware of the potential high 
health-care costs a patient might incur if access to a needed drug was poor. 
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It is difficult to conclude whether or not formularies compromise patient care, but if 
the proper formulary development guidelines are followed, it should not be an issue. It 
also seems likely that a physician would be ethically required to prescribe a different drug 
if the patient was not responding to a previous substance. 
Health-Care Expenditures & Formularies 
When a formulary is developed, one goal is naturally to cut down on medical costs, 
but is that really happening? The Institute for Clinical Outcomes Research recently 
conducted a study on closed formularies by looking at the care of almost 13,000 patients 
in 6 HMO's across the country. [35] The institute found the less drugs that were available 
to patients in different therapeutic classes, the higher the costs were for prescription drug 
costs, along with increased hospitalizations and office visits.[35] It is hypothesized this 
was the case because of a few patients who did not respond well to drugs on a formulary 
and therefore drove up costs.[35] 
One specific example of the reduced number of prescriptions involved asthma 
treatment. Patients with the least severity of asthma averaged 8.4 prescriptions per year 
with no drug restrictions. However, in plans where 75% of asthma products were not 
available, patients averaged 26.3 prescriptions per year. [35] In the case of 50 patients 
with severe asthma, researchers found those whose formulary restricted the usage of 
inhaled steroids also had to deal with an increased number of emergency room and 
physicians visits, along with no long term relief of asthma symptoms. [35] 
One flaw in this closed formulary study is the failure to taken into account the 
HMO's ability to have access to discounted drugs. The study set its cost data based on 
average wholesale price(A WP).[35] As mentioned earlier in this paper, the discount for 
managed care plans from AWP is 15% for brand name drugs and 50% for generics. 
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Health plan administrators often argue that if formularies did not save money, why 
would widespread use of them occur? It is agreed upon that a drug list which is very 
restrictive could increase costs, but a well-designed formulary where patient well-being is 
the first priority should save money.[41] According to a pharmacy benefit manager at 
National Medical Health Card Systems, formularies typically save 5% to 10% on overall 
health care costs.[41] More specifically, open formularies with a three-tier copay design 
have also proven to save money in most cases. Formulary Journal reports that in a Scott-
Levin survey, 71 % of HMO pharmacy executives said their three-tier plan has saved 
money, and 75% of PBM pharmacy executives report the same.[45] 
Rob Damler, a health actuary with Milliman USA in Indianapolis, presents another 
argument against the closed formulary study. One might assume that in a non-formulary 
situation, physicians would prescribe the most effective drug in every instance. 
However, this does not always happen. In Damler's experience, he has come across 
many situations where drugs that have a higher switch rate(a patient switching from drug 
A to drug B) or noncompliance rate(a patient stops taking the drug) will have the greater 
market share. His explanation is that many physicians will simply prescribe the drug 
they are most comfortable with, and not the drug that will be most beneficial. [54] 
Damler makes it clear that a non-formulary setting is by no means a perfect world, and 
should not necessarily be used as a comparison to a formulary environment. [54] 
-Political & Government Developments with Formularies 
Medicaid Plans 
Recently, a few states have turned to prescription drug formularies for their 
Medicaid plan to help save money for their already tight budgets. Collectively, the 50 
states spend over $25 billion on prescription drugs through their Medicaid plans, and 
these costs are expected to increase just as quickly as the overall expenditure on 
drugs. [48] 
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Maine was the first state to develop a formulary for their Medicaid plan. MaineRx, 
the state's drug plan for those who are uninsured, negotiated with drug manufacturers for 
discounts and threatened them with price controls if they did not give any price 
concessions.[46] Florida then shortly followed in the same direction as Maine. 1990 
Medicaid laws require drug manufacturers to sell their drugs to Medicaid programs at a 
price that is equal to the lowest price they offer to any group.[48] Florida took this one 
step further by demanding that drug manufacturers give the Medicaid program an 
additional 6% discount. Florida is expected to save an estimated $100 million in 2002 
because of its new Medicaid formulary. [48] 
Michigan, faced with a $42 million budget shortfall for 2002 and drug costs that 
had doubled in only two years, decided to take even more dramatic action.[48] The 
Michigan Medicaid plan took 40 therapeutic classes, and selected two "best in class" 
drugs based officially on "clinical effectiveness and safety".[47] If a manufacturer 
wished to be on a preferred list, they had to offer discounts which would match the prices 
for the two drugs in each category.[47] A drug not on the preferred list could still be 
prescribed, but a physician would have to get special approval to prescribe the drug, and 
this is generally seen as a major deterrent of utilization. [47] 
- These recent formularies have had a dramatic influence on the Medicaid market 
share of certain drugs. For example in Florida, the market share of 
Prilosec(antiu1cerants) went from 30% to 4% in the span of 3 months. Likewise, 
Prevacid(antiu1cerants) saw its market share increase from 43% to 65%.[48] Guess 
which one made Florida's preferred list? 
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In Maine, there is evidence formularies are influencing not only Medicaid market 
share, but even non-Medicaid customers, although to a lesser degree. Protonix saw its 
market share jump from 3% to 75% since it became the preferred heart-bum drug in 
Maine's plan. Additionally, with non-Medicaid customers, there was a 10% increase in 
market share.[48] The belief of pharmaceutical manufacturers is that doctors will 
prescribe Medicaid drugs out of habit, even to non-Medicaid patients. [48] 
The pharmaceutical industry has been outraged by the developments in Maine, 
Florida, and Michigan. Lawsuits in all three states have failed to put a stop to the 
Medicaid formularies. [49] In Europe, where countries have drug policies similar to 
Michigan's, pharmaceutical profits have been hurt gravel y. [48] If this is allowed to 
happen in the United States, it is argued by many that drug manufacturer's will have less 
incentive to conduct research and bring new drugs to the market place.[48] However, 
one pharmaceutical industry source believes this would not be the case. Mary Kuhn 
believes that formularies certainly have decreased the profits of the industry and have 
changed the way drugs are marketed and sold, but does not believe it has discouraged 
research. [31] 
The industry plans on beginning an intense campaign against drug restrictions in 
March 2002 by lining up physicians and consumer advocates against formularies.[49] 
Don Rounds of the Consumer Alliance based in Lansing, Michigan, believes state 
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Medicaid programs such as Michigan's are trying to "balance their budgets on the poor 
and elderly" and believes drug restrictions are "medically and morally wrong".[49] 
However, from discussion with those having knowledge of the Michigan Medicaid plan, 
Rob Damler feels that safety and effectiveness were the primary concern when picking 
the best drugs in each therapeutic c1ass.[54] 
The drug industry believes programs such as Michigan's are not distinguishing 
between old and new drugs. For example in Michigan, in the antiarthritic class, Celebrex 
and Vioxx were left off the list in favor of the generic naproxen, which costs $130 
less.[48] It can be easily seen from this one example why states are very eager to 
implement formularies for their Medicaid programs, but drug manufacturers cringe at the 
thought of seeing them in all 50 states. If Medicaid formularies are allowed to stand in 
court, expect many other states to follow through with formularies of their own.[ 49] 
A campaign promise in the 2000 presidential election by both candidates was a 
Medicare prescription drug benefit. Due to the events of September 11th and the budget 
shortfall, this has taken a backseat in 2002, but when the issue is brought up again, there 
is a good possibility formularies will be used to make a Medicare drug benefit 
affordable. [47] 
From the recent developments with several states' Medicaid plans, it is obvious that 
formularies will continue to make national news. Without question, these states feel 
formularies will save them money on their prescription drug costs. It may be argued by 
some the formularies will increase overall health expenditures because the cheaper drugs 
are not as effective and will lead to other medical expenses, but if these states follow the 
proper formulary development guidelines, this should not be a problem. To provide 
further evidence for the value of formularies, in a 1996 study, it was found elimination of 
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a restrictive Medicaid formulary did increase the number of prescriptions for the top 200 
drugs, but there was very little therapeutic value gained by this development.[24] 
Remembering Michigan's plan resembles formularies in European nations, a study done 
by D.J. Gross found no evidence that formularies in Europe reduced the quality of drug 
coverage. [24] The pharmaceutical industry's outrage over the recent Medicaid 
formularies are more likely related to profits than medical or safety concerns. 
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Summary & Commentary 
From the first half of this paper, it is obvious usage and expenditures are increasing 
rapidly on prescription drugs in the United States. However, although this is certainly a 
concern for the future, it should not be looked as necessarily a bad situation. Many new 
drugs are being offered for diseases or ailments that would result in hospitalization or a 
decreased quality of life in the recent past. 
The aging population is another unpreventable factor contributing to drug spending. 
As the American population grows older as a whole, health expenditures in all areas will 
be taxed heavier than ever before. Prescription drugs will help alleviate the heavy burden 
on other medical resources, and allow these resources to be utilized by the patients who 
truly need the services. 
The increased amount of third party coverage for Americans, usually in the form of 
an employer health plan, has decreased the amount of money we spend on prescriptions 
as a percentage of overall drug expenditures. The robust U.S. economy in the last decade 
had undoubtedly made some health plans very lucrative in order to try and retain 
employees. A quality prescription drug benefit is an especially desirable workplace 
perk. 
Patent laws are unquestionably necessary so that drug manufacturers have the 
incentive to make an investment in time and money when developing a new drug. 
Without patents, research and development would be stagnant, and the government 
would likely be the only means of furthering medical advances. Any reasonable person 
would agree our current economic system is a much better way of giving people the 
proper reward for their creativity and hard work. 
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At the same time, there should also be scrutiny on drug manufacturers who keep 
trying to delay the expiration of a patent on a popular drug. Currently, companies can 
extend patents by 30 months simply by telling the government a generic manufacturer 
would infringe on their patent.[51] One very good example is the drug Prilosec which 
had $4.7 billion in sales in the United States alone in 2000. The patent for the drug was 
supposed to expire in the fall of 2001, but the manufacturer was able to get an 
extension.[51] What is this costing providers? The chief pharmacist at General Motors 
reports it loses $1.3 million every month because it cannot buy the generic version of the 
drug for which 346,000 prescriptions are written each month.[51] 
Direct-to-consumer advertising is one topic that should be studied further, and will 
become more controversial as time passes. In a study released in March 2002, it was 
found only 50 drugs out of 9,482 were responsible for almost a $14 billion increase in 
2001 drug expenditures. Amazingly, the other drugs only contributed to a roughly $8.5 
billion rise. [52] Also, the price difference between the top 50 drugs and the average for 
the rest of the market was a little over $31.[52] Not surprisingly, many of the top 50 
drugs also had the most spending in advertising.[52] 
When consumers see a famous baseball player, NASCAR driver, or even ex-
presidential candidate pitching a new drug, many will have a much stronger interest in 
taking this specific drug themselves. The question is not whether or not direct-to-
consumer advertising works, but whether or not it is an ethical practice. Should not a 
physician be the sole person determining whether or not a person should be on any 
prescription? Patients should be able to trust that their physicians will make a decision in 
their best interest. 
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When doing advertising to consumers, it seems much more ethical just to be 
advertising for a certain disease or ailment, and not a specific drug. If consumers see this 
kind of advertising, they will know drugs are available for these conditions, and then will 
be able to ask their doctor whether or not they need a prescription. If your car breaks 
down, does not the average person let the mechanic decide what needs to be fixed on the 
car, rather than telling the mechanic what to do and how to do it? A similar and 
hopefully much stronger relationship should exist between the physician and patient. 
If one drug in a therapeutic class is clearly more effective than other substances, the 
best drug should naturally be the one prescribed most often. The pharmaceutical industry 
should concentrate their product-specific advertising at physicians who can then make 
informed decisions about the effectiveness of a particular product. 
Ironically, drug manufacturers and insurers have completely opposite goals when it 
comes to pharmaceutical usage. Manufacturers would like to increase demand as much 
as possible, whereas insurers would like to see that same demand constrained. [50] It is 
foolish to believe that there are or should be no cost constraints in the United States' 
health care system. In order for as many Americans as possible to receive proper health 
care, controls must be in place to prevent over-utilization of certain services, and 
prescription drugs are no exception. In the second half of this paper, it was seen that 
formularies are becoming a widespread means of managing drug usage. 
Unfortunately, when many people hear the word "formulary," they automatically 
think of not receiving the best prescription drugs, and believe their health is being 
compromised for cost savings. This could be the case when a formulary is not selected 
properly, but if the proper guidelines are followed, both the consumer and insurer should 
benefit. Safety, how well does the drug work, and is the drug needed for therapeutic 
-. 
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purposes should be the primary concerns of any Pharmacy & Therapeutics committee 
when selecting drug for a formulary.[53] After these areas have been properly addressed, 
the P&T committee can then look at how much the prescription will cost. 
The open formulary gives more options than a closed formulary, and consumers 
usually like more options. A health plan with an open formulary is justified in setting up 
tiered copays. If there was no difference in copay between various drugs, what incentive 
would the consumer have to purchase a generic rather than a costly brand-name drug? 
Tiered copays are also a good way of separating drugs that are necessary for survival, 
rather than drugs that merely enhance your lifestyle. By making these lifestyle drugs 
more expensive, the PBM or insurer can save money on their overall plan and allow 
consumers to purchase the truly necessary drugs at a lower price. 
The second half of the paper also examined the power formularies have over drug 
manufacturers and pharmacy networks. By yielding a large amount of enrollees and the 
ability to shift market share, a PBM can negotiate for discounts from manufacturers, 
pharmacies, or both. The consumer benefits from these discounts by paying less out of 
his or her pocket than a person not enrolled in a health plan. 
Several states have also realized they can put considerable pressure on drug 
manufacturers to lower drug costs in Medicaid programs. The actions of Maine, Florida, 
and Michigan could establish a model for Medicaid formulary development that would be 
followed by other states. The largest opponent of these new Medicaid plans are the drug 
manufacturers, which view the formularies as an added obstacle considering law already 
requires drug manufacturers to give Medicaid plans the "best" price. With around 50 
million Americans in the Medicaid program, the drug manufacturers will certainly have 
decreased profits if every state adopts similar programs to Michigan, Florida, and Maine. 
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Physicians often have trouble adhering to formularies, but fortunately web-based 
tools will make this easier and will also cut down on costly prescription errors. These 
tools are not widespread at the present time, but their implementation is likely to happen 
soon on a wider basis.[53] The web-based tools will also benefit pharmacists by 
reducing the number of times they have to call the physician about illegible prescriptions, 
formulary compliance, or switching to a generic. Consumers will be more informed 
about their choices through the web-based tools, and will instantly be able to see the cost 
of a prescription and then have it faxed to the pharmacy. When web-based tools become 
commonplace, physicians, pharmacists, insurers, and consumers will all benefit. 
Conclusion 
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In conclusion, the pharmaceutical and managed care industry has and will continue 
to change drastically in future years. Regulations can be put in place, new drugs can be 
developed, health plans can be restructured, and new technology can allow old tasks to be 
done more efficiently. In these industries of change, it can be guaranteed drug 
manufacturers are going to make better and more specific drugs. Also, it is almost a sure 
bet formularies will be incorporated even more in designing the prescription drug benefit 
of a health plan. Americans will want the best drugs possible for their ailments, but at the 
same time, they do not want their medications to cost a fortune. With our added 
dependence on prescription drugs for our health needs, a well developed and managed 
formulary can help our society by serving two of our basic prescription drug wishes: 
access and affordability. 
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